Antheia

Antheia, Inc. is a synthetic biology company based in Menlo Park, California, founded in 2015 from the Smolke Lab at Stanford University. The company employs around 50 people and focuses on reengineering pharmaceutical supply chains. Antheia utilizes synthetic biology to produce essential medicines that are traditionally sourced from plants, emphasizing access to medicine, sustainability, equity, resilience, transparency, and safety in manufacturing. Antheia specializes in biomanufacturing Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) using genetically engineered yeast. Their platform allows for scalable production of complex molecules in controlled fermentation environments, enabling rapid-response manufacturing to address drug shortages. The company serves the pharmaceutical industry, particularly in areas like palliative care, cancer treatment, and neurological therapies. Antheia has raised $73 million in venture capital to enhance its production capabilities and is focused on growth and recruitment to expand its operations.